Survival after Surgery following Chemotherapy for Non-Small-Cell Lung Cancer

A retrospective study was carried out on 74 patients with advanced non-small-cell lung cancer (52 in stage IIIA, 22 in stage IIIB) who received platinum-based induction chemotherapy in doublets and triplets, followed by tumor resection. Thirty-day postoperative mortality was 5.4% (4 patients); 5 pat...

Full description

Saved in:
Bibliographic Details
Published in:Asian cardiovascular & thoracic annals 2010-02, Vol.18 (2), p.141-146
Main Authors: Molnar, Tamas F, Baliko, Zoltan, Sarosi, Veronika, Horvath, Peter Ors
Format: Article
Language:English
Subjects:
Actuarial Analysis
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - therapy
Combined Modality Therapy
Female
Humans
Lung Neoplasms - mortality
Lung Neoplasms - therapy
Lymphatic Metastasis
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Platinum Compounds - therapeutic use
Pneumonectomy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A retrospective study was carried out on 74 patients with advanced non-small-cell lung cancer (52 in stage IIIA, 22 in stage IIIB) who received platinum-based induction chemotherapy in doublets and triplets, followed by tumor resection. Thirty-day postoperative mortality was 5.4% (4 patients); 5 patients in stage IIIB and 17 in stage IIIA did not respond, but the other 47 (63.5%) were downstaged to < IIIA (26 were downstaged to stage I, 20 to stage II, and 1 had complete remission). There was no change in T factor in 22 (30%) patients, nor in N factor in 21 (28%). The actuarial 5-year survival rate for patients in postoperative stages IIIA and IIIB was 0.496; survival was significantly longer in patients who responded to therapy. Parallel improvement in both T and N status predicted worse survival than a multistage regression in any single factor. N status was found to be a stronger survival indicator than T status. Cell type did not influence the response rate or outcome. Induction chemotherapy significantly improved survival in patients who responded, despite a poor prognosis.
ISSN:0218-4923
1816-5370
DOI:10.1177/0218492310361271